Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment Clinical Trial

Official title:

A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05490030
• Other study ID #: CTNO155A12106
• Status: Withdrawn
• Phase: Phase 1
• Start date: March 6, 2025
• Est. completion date: June 26, 2025

Study information

• Verified date: February 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155.

The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

Description:

This is a study to evaluate the PK of TNO155 in participants with mild, moderate or severe hepatic impairment compared to matched healthy control participants with normal hepatic function.

The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment (mild, moderate, or severe) according to a classification score determined at the screening visit and confirmed unchanged at the baseline visit.

Each participant in the healthy control group may be matched to 1 or more evaluable participants with hepatic impairment with respect to age (± 10 years), body weight (± 20%), sex and smoking status (smoker vs. non smoker). Each participant in the control group can be matched to participants from any hepatic impairment group but cannot be matched to more than 1 participant from the same hepatic impairment group.

All participants will be domiciled from Day -1 until Day 11. All participants should have a poststudy safety follow-up contact conducted approximately 30 days after administration of study treatment. The study will be considered complete once all the participants have finished the required assessments, dropped out, or been lost to follow-up before completing the required assessments.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 26, 2025
• Est. primary completion date: June 26, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

All participants Participants must weigh at least 50 kg and no more than 120 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, for healthy participants. For participants with hepatic impairment without overt ascites, the BMI should be within the range of 18.0 to 40.0 kg/m2. For participants with hepatic impairment with overt ascites, the BMI should be within the range of 18.0 to 45.0 kg/m2.

Group 1

•Each healthy control participant must match in age (± 10 years), sex, body weight (± 20%), and smoking status to at least 1 hepatic impairment participant in Groups 2, 3 and/or 4.

Groups 2 to 4 •Participants with mild, moderate or severe hepatic impairment must have a Child-Pugh score clinically determined at screening and confirmed unchanged at baseline calculated as per the Child-Pugh classification in line with the hepatic impairment status of each Group

Exclusion Criteria:

All Participants

• Use of drugs (prescription, non-prescription and herbal remedies such as St John's wort) known to affect CYP3A or UGT1A3, including UGT1A3 inhibitors and inducers and strong and moderate CYP3A inhibitors and inducers, within 4 weeks prior to dosing until completion of the End of Study Visit.

• Acute or chronic hepatitis B or C infection or active infection requiring therapy that will not be completed before screening.

Left ventricular ejection fraction (LVEF) < 50% or below the institutional standard lower limit, whichever is higher, as determined by multiple gated acquisition (MUGA) scan or Trans-thoracic echocardiography (TTE) at screening or baseline.

•At screening, history of retinal vein occlusion (RVO) or presence of predisposing factors to RVO or central serous retinopathy, or any other clinically significant ophthalmologic abnormalities determined by an ophthalmologist.

Group 1

• Any single parameter of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) exceeding 2.5 × upper limit of normal (ULN) or total bilirubin = 1.5 ULN OR any elevation above ULN of more than 1 parameter of ALT, AST, GGT, ALP, or serum bilirubin at screening or baseline.

• Impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen and/or other urea values outside local laboratory ranges or abnormal urinary constituents at screening or baseline.

Groups 2 and 3

• Severe complications of liver disease within the preceding 3 months prior to dosing.

• Hospitalization due to liver disease within the preceding 1 month prior to dosing.

• Participant has received liver transplant at any time in the past and is on immunosuppressant therapy.

• Participants requiring paracentesis more than every 3 weeks for the management of ascites are excluded.

Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Hepatic Impairment
• Liver Diseases

Intervention

Drug:
• TNO155
Single oral dose of TNO155 on Day 1

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals	Pharmaceutical Research Associates

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155	AUClast will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Primary	AUC from time zero to time "t" (AUC0-t) of TNO155	AUC0-t will be calculated as needed based on TNO155 plasma concentrations and non-compartmental methods. The definition of time "t" may be data-driven post-hoc to mitigate treatment bias due to within participant differences in Tlast between the treatments, or may be selected to allow between-study exposure comparisons that use a common time window.	Up to 240 hours post single dose
Primary	AUC from time zero to infinity (AUCinf) of TNO155	AUCinf will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Primary	Maximum (peak) observed plasma concentration (Cmax) of TNO155	Cmax will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Primary	Time to reach maximum observed plasma concentration (Tmax) of TNO155	Tmax will be calculated based on TNO155 plasma concentrations and non-compartmental methods	Up to 240 hours post single dose
Primary	Elimination half-life (T1/2) of TNO155	T1/2 will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Primary	Sampling time of the last measurable plasma concentration (Tlast) of TNO155	Tlast will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Primary	Apparent plasma clearance (CL/F) of TNO155	CL/F will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Primary	Apparent volume of distribution during terminal phase (Vz/F) of TNO155	Vz/F will be calculated based on TNO155 plasma concentrations and non-compartmental methods.	Up to 240 hours post single dose
Secondary	Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)	Incidence of AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.	Up to 30 days post single dose
Secondary	Unbound Cmax (Cmax,u) of TNO155	Cmax,u will be calculated based on the unbound fraction of TNO155 in plasma.	Up to 240 hours post single dose
Secondary	Unbound AUClast (AUClast,u) of TNO155	AUClast,u will be calculated based on the unbound fraction of TNO155 in plasma.	Up to 240 hours post single dose
Secondary	Unbound AUCinf (AUCinf,u) of TNO155	AUCinf,u will be calculated based on the unbound fraction of TNO155 in plasma	Up to 240 hours post single dose
Secondary	Unbound CL/F (CL/F,u) of TNO155	CL/F,u will be calculated based on the unbound fraction of TNO155 in plasma.	Up to 240 hours post single dose
Secondary	Renal clearance (CLr) of TNO155	CLr will be calculated based on urinary excretion data of TNO155.	Up to 240 hours post single dose
Secondary	Apparent non-renal clearance (CLNR/F) of TNO155	CLNR/F will be calculated based on urinary excretion data of TNO155.	Up to 240 hours post single dose
Secondary	Fraction of dose excreted in urine (fe) of TNO155	Fe will be calculated based on urinary excretion data of TNO155.	Up to 240 hours post single dose